CODX
Roadshow mode: activated
Co-Diagnostics is heading to WHX Labs Johannesburg from October 6th to October 8th, where it plans to spotlight its Co-Dx PCR platform and Co-Dx PCR MTB test. Think of it as a science fair booth, except the stakes are a lot higher and the swag probably still costs less than your average biotech lunch.
The Ebola angle is the real eyebrow-raiser
The company also said an Ebola assay is in development for decentralized testing on the Co-Dx PCR platform. That matters because a credible, portable diagnostic for a disease like Ebola could broaden the platform’s relevance beyond the usual lab-demo chatter.
Why investors should keep one eye open
This isn’t a near-term sales print or a flashy FDA win, so don’t expect the market to throw a parade. But updates like this can still matter for small-cap diagnostics names:
- they help keep the product story alive
- they give investors a peek at pipeline breadth
- they can support partnership or commercial conversations down the road
Big picture: Co-Diagnostics is still in “show, don’t tell” mode — but in biotech, sometimes the booth is where the future starts sniffing around.